<DOC>
	<DOCNO>NCT00884533</DOCNO>
	<brief_summary>This study randomise double blind , parallel group , evaluate effect repeat oral dos RSG- XR 21 day QTc interval compare placebo population healthy adult male female .</brief_summary>
	<brief_title>QTc Study Rosi XR Healthy Volunteers</brief_title>
	<detailed_description>An extended release ( XR ) formulation rosiglitazone maleate ( RSG ) , new formulation rosiglitazone , investigated treatment patient mild moderate Alzheimer 's disease ( AD ) . This study randomise double blind , parallel group , evaluate effect repeat oral dos RSG- XR 21 day ( due long half-life main metabolite M10 ) QTc interval compare placebo population healthy adult male females 18 45 year age . Moxifloxacin , drug well-quantified QTc prolongation , include positive control order validate ability study detect small change QTc .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male female volunteer age 18 45 Female non child bear potential child bear potential must use adequate contraception duration study 14 day last dose Body weight great equal 45 kg BMI within range 19 32 inclusive Subjects must provide full write informed consent Cardiac conduction abnormalities Any history myocardial infarction , syncope , cardiac arrhythmia history uncontrolled hypertension unstable heart disease Subjects systolic blood pressure outside range 90 150 mmHg diastolic blood pressure outside range 50 100 mmHg Subjects personal family history QTc prolongation unexplained cardiac arrest . Has history illicit drug use alcohol abuse within past year positive prestudy test alcohol , cotinine , drug abuse Screening prior start dose Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase value great 2.5 time ULN , total bilirubin value &gt; 1.5 time upper limit normal ( ULN ) , history severe hepatobiliary disease ( e.g . hepatitis B C , cirrhosis , ChildPugh Class B/C ) A positive test Screening Hepatitis B , Hepatitis C , Human Immunodeficiency Virus ( HIV ) Use agent know inhibit induce cytochrome CYP3A4 enzymes within 7 day prior first dose study drug ( include food supplement grapefruitcontaining product , mustard green , kale , kohlrabi , broccoli , collard green , brussel sprout , watercress , charbroiled meat St. John 's Wort Use prescription nonprescription drug , particular drug know inhibit induce CYP2C8 , vitamin ( exception may consider casebycase basis GSK medical monitor ) , herbal dietary supplement within fourteen day prior first dose study drug Lactating pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>QTc</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>rosiglitazone XR</keyword>
	<keyword>cardiac conduction</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>